PRLD Insider Trading Activity and SEC Form 4 Filings
PRLD insider trading summary
No open-market insider purchases or sales of Prelude Therapeutics Inc (PRLD) have been reported on SEC Form 4 in the past 12 months.
Latest PRLD insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 25, 2025 | Andrew Combs | Chief Chemistry Officer | Buy | $69K (100,000 @ $0.69) |
| Mar 25, 2025 | Krishna Vaddi | CEO | Buy | $467K (675,000 @ $0.69) |
| Mar 21, 2025 | Krishna Vaddi | CEO | Buy | $11K (15,000 @ $0.73) |
| Mar 20, 2025 | Krishna Vaddi | CEO | Buy | $4K (5,416 @ $0.73) |
| Mar 17, 2025 | Krishna Vaddi | CEO | Buy | $7K (9,106 @ $0.75) |
| Mar 14, 2025 | Krishna Vaddi | CEO | Buy | $23K (29,999 @ $0.75) |
| Mar 13, 2025 | Krishna Vaddi | CEO | Buy | $36K (50,000 @ $0.72) |
| Mar 12, 2025 | Krishna Vaddi | CEO | Buy | $34K (47,500 @ $0.71) |
| Dec 31, 2024 | Krishna Vaddi | CEO | Buy | $6K (5,000 @ $1.21) |
| Dec 30, 2024 | Krishna Vaddi | CEO | Buy | $12K (10,000 @ $1.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.